Wyeth’s Pristiq Best-Case Launch Scenario Targets Menopause Market
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA is re-inspecting the manufacturing facility cited in an “approvable” letter for Wyeth’s initial NDA for major depressive disorder.